Should You Sell This Stock Following a Regulatory Roadblock?
Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its financial results have generally been robust excluding its coronavirus antibody, whose sales are dropping.
However, every company, even the best ones, sometimes encounters headwinds. Regeneron is no exception. The drugmaker recently received a rejection letter from U.S. regulators regarding an application it submitted for one of its pipeline candidates. Let's look at what this means for the business and its shareholders.
Source Fool.com
Regeneron Pharmaceuticals Inc. Stock
With 44 Buy predictions and 1 Sell predictions Regeneron Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 1032 € shows a slightly positive potential of 5.31% compared to the current price of 980.0 € for Regeneron Pharmaceuticals Inc..